| Revision as of 19:08, 5 October 2006 editCollegehealth-e (talk | contribs)21 editsNo edit summary← Previous edit | Revision as of 19:11, 5 October 2006 edit undoCollegehealth-e (talk | contribs)21 editsNo edit summaryNext edit → | ||
| Line 40: | Line 40: | ||
| One well known metabolic catalyst involved is a specific ] ] known as 2D6, or ]. A significant portion of the population has a functional deficiency in this enzyme (and are known as poor CYP2D6 metabolizers). As CYP2D6 is the primary ] in the inactivation of dextromethorphan, the duration of action and effects of dextromethorphan are significantly increased in such poor metabolizers. Deaths and hospitalizations have been reported in recreational use by poor CYP2D6 metabolizers.{{verify source}} | One well known metabolic catalyst involved is a specific ] ] known as 2D6, or ]. A significant portion of the population has a functional deficiency in this enzyme (and are known as poor CYP2D6 metabolizers). As CYP2D6 is the primary ] in the inactivation of dextromethorphan, the duration of action and effects of dextromethorphan are significantly increased in such poor metabolizers. Deaths and hospitalizations have been reported in recreational use by poor CYP2D6 metabolizers.{{verify source}} | ||
| A large number of medications (including ]s) are potent inhibitors of CYP2D6 ''(see ] article)''. There exists, therefore, the potential of drug-drug interactions between dextromethorphan and concomitant medications. There have been reports of fatal consequences arising from such interactions. | A large number of medications (including ]s) are potent inhibitors of CYP2D6 ''(see ] article)''. There exists, therefore, the potential of drug-drug interactions between dextromethorphan and concomitant medications. There have been reports of fatal consequences arising from such interactions.<ref name=Jones>{{cite journal | author =Jones K, Taranto M | year =2006 | title = Illicit Drug Manual: Dextromethorphan ("Robo-tripping") | journal =collegehealth-e | volume =1 | issue =4 | pages =13-17 }} }}</ref> | ||
| Dextromethorphan crosses the ], and the following pharmacological actions have been reported: | Dextromethorphan crosses the ], and the following pharmacological actions have been reported: | ||
Revision as of 19:11, 5 October 2006
Pharmaceutical compound | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic (CYP2D6, CYP3A4 and CYP3A5-mediated) |
| Elimination half-life | 1.4–3.9 hours |
| Excretion | Renal |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.004.321  |
| Chemical and physical data | |
| Formula | Template:Carbon18Template:Hydrogen25Template:NitrogenTemplate:Oxygen |
| Molar mass | 271.4 g/mol |
Dextromethorphan (DM or DXM) is an antitussive drug that is found in many over-the-counter cold and cough preparations, usually in the form of dextromethorphan hydrobromide. It is also used as a recreational drug.
Chemistry
Dextromethorphan is a salt of the methyl ether dextrorotatory isomer of levorphanol, a narcotic (opioid) analgesic (and DXM itself is an enantiomeric isomer, that is, a mirror image in the 3D space, of levomethorphan, a substance considered an opioid). It is chemically named as 3-methoxy-17-methyl-9(alpha), 13(alpha), 14(alpha)-morphinan hydrobromide monohydrate. DXM occurs as white crystals, is sparingly soluble in water, and freely soluble in alcohol. The drug is dextrorotatory in water (at 20 degrees Celsius, Sodium D-line) with a specific rotation of +27.6 degrees.
Indications
The FDA approved dextromethorphan for over-the-counter sale as a cough suppressant in 1958. This filled the need for a cough suppressant lacking the abuse liability and addictive properties of codeine phosphate, the most widely used cough medication at the time. The advantage of dextromethorphan preparations over those containing codeine (now prescription only in the United States) was the lack of physical addiction potential and sedative side-effects, although as with most cough supressants, studies show that its effectiveness is highly debatable. See also: Cough medicine controversy
Pharmacodynamics
At therapeutic doses, the drug acts centrally to elevate the threshold for coughing, without inhibiting ciliary activity. Dextromethorphan is rapidly absorbed from the gastrointestinal tract, and exerts its activity within 15 to 60 minutes of ingestion. The duration of action after oral administration is approximately three to eight hours. Because administration of DXM can be accompanied by histamine release, its use in atopic children is very limited.
The average dosage necessary for effective antitussive therapy is between 10mg and 30mg every four to six hours.
According to the WHO committee on Drug Dependence, dextromethorphan, when used recreationally (see non-medical use of dextromethorphan), does not produce physical addiction but can generate slight psychological dependence in some users.
Clinical pharmacology
 | This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Dextromethorphan" – news · newspapers · books · scholar · JSTOR (Learn how and when to remove this message) |
Following oral administration, dextromethorphan is rapidly absorbed from the gastrointestinal tract, where it enters the bloodstream and crosses the blood-brain barrier. The first-pass through the hepatic portal vein results in some of the drug being metabolized into an active metabolite of dextromethorphan, dextrorphan, the 3-hydroxy derivative of dextromethorphan. The therapeutic activity of dextromethorphan is believed to be caused by both the drug and this metabolite. Dextromethorphan is metabolized by various liver enzymes and subsequently undergoes O-demethylation (producing dextrorphan), N-demethylation, and partial conjugation with glucuronic acid and sulfate ions. Hours after dextromethorphan therapy, (in humans) the metabolites (+)-3-hydroxy-N-methylmorphinan, (+)-3-morphinan, and traces of the unchanged drug are detectable in the urine.
One well known metabolic catalyst involved is a specific cytochrome P450 enzyme known as 2D6, or CYP2D6. A significant portion of the population has a functional deficiency in this enzyme (and are known as poor CYP2D6 metabolizers). As CYP2D6 is the primary metabolic pathway in the inactivation of dextromethorphan, the duration of action and effects of dextromethorphan are significantly increased in such poor metabolizers. Deaths and hospitalizations have been reported in recreational use by poor CYP2D6 metabolizers.
A large number of medications (including antidepressants) are potent inhibitors of CYP2D6 (see CYP2D6 article). There exists, therefore, the potential of drug-drug interactions between dextromethorphan and concomitant medications. There have been reports of fatal consequences arising from such interactions.
Dextromethorphan crosses the blood-brain barrier, and the following pharmacological actions have been reported:
- NMDA glutamatergic receptor antagonist
- Dopamine reuptake inhibitor
- σ1 and σ2 receptor agonist (Zhou & Musacchio, 1991)
- α3β4 nicotinic receptor antagonist
- Serotonin reuptake inhibitor
History
Dextromethorphan was first patented with U.S. patent 2,676,177, and was approved for over-the-counter purchase as an antitussive in 1958.
During the 1960s and 1970s, DXM became available in an over-the-counter tablet form by the brand name Romilar. It was put on the shelves in hopes of cutting down on codeine cough remedies. In 1973, Romilar was taken off the shelves after a burst in sales due to common recreational use. It was then replaced by cough syrup, in an attempt to cut down on recreational usage.
Fibromyalgia Treatment
Dextromethorphan is currently being investigated as a potential treatment for fibromyalgia symptoms.
Recreational use
| This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Dextromethorphan" – news · newspapers · books · scholar · JSTOR (Learn how and when to remove this message) |
Since their introduction, preparations containing the over-the-counter drug dextromethorphan have been used in a manner inconsistent with their labeling, often as a recreational drug or to induce intoxication (sometimes referred to as "robo-tripping"). Dextromethorphan has little to no psychological effect in the doses used medically, however alteration of consciousness generally occurs following ingestion of approximately 7 to 50 times the therapeutic dose over a relatively short period of time.
People who study the specific effects of psychotropic substances classify DXM as a dissociative drug, a major subclass of hallucinogenic drugs, along with Ketamine and Phencyclidine. It generally does not produce withdrawal symptoms characteristic of physically addictive substances, but psychological addiction has been reported by some users.
However, many chemical dependency treatment centers have been reporting many young people addicted to DXM. Their withdrawal symptoms were documented as being identical to those of the illegal opiate, heroin.
DXM, when consumed in low recreational doses (usually under 100mg), is often described as having a buoyant, vaguely psychedelic effect similar to a mixture of alcohol, opiates, and nitrous oxide. With higher doses, intense euphoria and vivid imagination may occur as bizarre feelings of dissociation increase. With very high doses, profound alterations in consciousness have been noted, and users often report out of body experiences or temporary psychosis. In 1981, a paper by Gosselin estimated the lethal dose between 50 and 500 mg/kg.
Individual reactions to recreational doses of Dextromethorphan vary widely. Some find the effects of the drug to be immensely pleasurable, similar to a combination of opiates and hallucinogens, while others find that the drug produces dysphoria, panic, or dread.
Physical side effects that can occur after ingestion of recreational doses of DXM include a blotchy skin rash, itching (sometimes referred to as "robo itch," short for "Robitussin itch"), and sweating. Many people vomit from recreational doses or feel ill for the first part of the “trip”. When taken in higher doses, side effects can include dilated pupils and loss of appetite, as well as shakiness.
See also
References
- Shulgin, Alexander (2003). "DXM (Dextromethorphan)". Ask Dr. Shulgin Online. Retrieved 2006-05-31.
{{cite web}}: External link in|work= - ^ Jones K, Taranto M (2006). "Illicit Drug Manual: Dextromethorphan ("Robo-tripping")". collegehealth-e. 1 (4): 13–17.fulltext pdf}}
- http://www.nhtsa.dot.gov/people/injury/research/job185drugs/dextromethorphan.htm
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list uids=10869398
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list uids=1636059
- http://www.insightrecovery.org/
External links
- Illicit Drug Manual: Dextromethorphan ("Robo-Tripping")
- Dextroverse
- Dextromethorphan FAQ at third-plateau.org
- Erowid